Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
Want to see IN:BAFNAPH full AI Analyst Report?
BAFNAPH Stock Chart & Stats
₹154.65
-₹1.34(-1.60%)
At close: 4:00 PM EST
₹154.65
-₹1.34(-1.60%)
Day’s Range― - ―
52-Week Range₹72.25 - ₹204.95
Previous CloseN/A
Volume2.58K
Average Volume (3M)1.19K
Market Cap
₹3.27B
Enterprise Value₹3.53B
Total Cash (Recent Filing)₹19.67M
Total Debt (Recent Filing)₹324.03M
Price to Earnings (P/E)48.5
Beta0.62
Next Earnings
May 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.70
Shares Outstanding23,656,336
10 Day Avg. Volume1,123
30 Day Avg. Volume1,187
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)2.09
Price to Sales (P/S)1.22
P/FCF Ratio-76.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business Model DiversityOperating both domestic manufacturing and export sales creates durable revenue diversification. Selling finished dosages to wholesalers, hospitals and overseas buyers supports scale, lowers single-market dependency, and provides multiple routes to sustain volumes and distribution over years.
Multi-year Revenue GrowthConsistent multi-year top-line growth through 2020–2025 indicates product traction and expanding market penetration. A rising revenue base supports higher manufacturing utilization, potential scale benefits, and a foundation for continued reinvestment and stable market positioning over the medium term.
Sound Equity Base / Manageable LeverageA stable equity base and moderate debt-to-equity ratio provide financial flexibility to fund capex and working capital without immediate refinancing stress. This balance sheet strength supports resilience to shocks and enables strategic investments that sustain long-term operations and growth.
Bears Say
Margin CompressionSustained compression of gross and net margins points to structural profitability pressure—likely from pricing, input cost inflation, or adverse product mix. Persisting margin erosion will reduce earnings power, constrain reinvestment capacity, and lower long-term returns on capital if not addressed.
Volatile / Negative Free Cash FlowVolatile and recently negative free cash flow undermines the firm's ability to self-finance growth and absorb shocks. Continued FCF instability increases reliance on external financing, raises liquidity and execution risk, and can limit sustained investment in capacity or new product development.
Recent Revenue ContractionA recent reported revenue decline of roughly 51% is a material structural warning sign. Continued topline contraction erodes economies of scale, magnifies margin pressure, and threatens long-term cash generation and market position unless management reverses the trend through market share recovery or new revenue streams.
Bafna Pharmaceuticals Limited News
BAFNAPH FAQ
What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?
Bafna Pharmaceuticals Limited lowest stock price was ₹72.25 and its highest was ₹204.95 in the past 12 months.
What is Bafna Pharmaceuticals Limited’s market cap?
Bafna Pharmaceuticals Limited’s market cap is ₹3.27B.
When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?
Bafna Pharmaceuticals Limited’s upcoming earnings report date is May 29, 2026 which is in 7 days.
How were Bafna Pharmaceuticals Limited’s earnings last quarter?
Bafna Pharmaceuticals Limited released its earnings results on Feb 11, 2026. The company reported ₹0.776 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.776.
Is Bafna Pharmaceuticals Limited overvalued?
According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here
What is Bafna Pharmaceuticals Limited’s EPS estimate?
Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bafna Pharmaceuticals Limited have?
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.
What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?
Bafna Pharmaceuticals Limited reported an EPS of ₹0.776 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BAFNAPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Krebs Biochemicals & Industries Ltd.
―
Mangalam Drugs & Organics Ltd.
―